Impact of Opioid Epidemic on Infective Endocarditis Outcomes in the United States: From the National Readmission Database

• Published in: The American journal of cardiology 2022-11, Vol.183, p.137-142
• Main Authors: Khayata, Mohamed, Hackney, Noah, Addoumieh, Antoine, Aklkharabsheh, Saqer, Mohanty, Bibhu D., Collier, Patrick, Klein, Allan L., Grimm, Richard A., Griffin, Brian P., Xu, Bo
• Format: Article
• Language: English
• Subjects: Amphetamines; Bacterial infections; Cocaine; Congestive heart failure; Demographics; Diabetes mellitus; Drug abuse; End-stage renal disease; Endocarditis; Epidemics; Hepatitis; Hepatitis C; Heroin; HIV; Hospital costs; Hospitalization; Human immunodeficiency virus; Hypertension; Infections; Kidney diseases; Morbidity; Mortality; Narcotics; Opioids; Pacemakers; Pandemics; Patients; Public health; Renal failure; Surgery; Vascular diseases; Viral infections
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2022.08.002

Infective endocarditis (IE) is associated with marked morbidity and mortality in the United States and parallels the opioid pandemic. Few studies explore this interaction and its effect on clinical outcomes. We analyzed contemporary patients admitted with IE to determine predictors of readmission in the United States. The 2017 National Readmission Database was used to identify index admissions in adults with the diagnosis of IE, based on the International Classification of Disease, 10th Revision codes. The primary outcome of interest was 30-day readmission. Secondary outcomes were mortality, hospital charges, and predictors of hospitalization readmission. Of 40,413 index admissions for IE, 5,558 patients (13.8%) were readmitted within 30 days. Patients who were readmitted were younger (55 ± 20 vs 61 ± 19 years, p